Cargando…

In vitro measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18F-FDG, gamma spectrometry and PET/CT

The standard treatment for head and neck squamous cell carcinoma (HNSCC) is radiotherapy, often in combination with chemotherapy or surgery. However, a novel monoclonal antibody, cetuximab (Erbitux(®)), has also been approved for patient therapy. The aim of present study was to develop an in vitro m...

Descripción completa

Detalles Bibliográficos
Autores principales: Matic, Natasa, Ressner, Marcus, Wiechec, Emilia, Roberg, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788167/
https://www.ncbi.nlm.nih.gov/pubmed/31620196
http://dx.doi.org/10.3892/ol.2019.10916
_version_ 1783458432308740096
author Matic, Natasa
Ressner, Marcus
Wiechec, Emilia
Roberg, Karin
author_facet Matic, Natasa
Ressner, Marcus
Wiechec, Emilia
Roberg, Karin
author_sort Matic, Natasa
collection PubMed
description The standard treatment for head and neck squamous cell carcinoma (HNSCC) is radiotherapy, often in combination with chemotherapy or surgery. However, a novel monoclonal antibody, cetuximab (Erbitux(®)), has also been approved for patient therapy. The aim of present study was to develop an in vitro method for the measurement of 18F-fluoro-2deoxy-D-glucose (FDG) to determine if cellular 18F-FDG uptake is associated with response to radiotherapy or cetuximab treatment. In the current study, HNSCC cell lines were treated with radiation or with cetuximab. Next, the uptake of 18F-FDG was measured using a gamma spectrometer (GS). Thereafter, uptake after radiation was measured first with GS and then compared with positron emission tomography (PET)/computed tomography (CT) imaging. Furthermore, the mRNA expression of glucose transporter 1 (GLUT1) was measured following cetuximab treatment via reverse transcription-quantitative PCR. A study protocol was developed to measure the cellular uptake of 18F-FDG via gamma-ray spectrometry and comparable results were obtained with those of clinical PET/CT. The results revealed a decrease in 18F-FDG after radiation and cetuximab treatment. The uptake of 18F-FDG following cetuximab treatment was significantly lower in the cetuximab-sensitive cell line UT-SCC-14 compared with the cetuximab-resistant cell lines UT-SCC-2 and UT-SCC-45. Furthermore, after treatment with cetuximab for 24 and 48 h, a significant increase in GLUT1 expression was detected in the sensitive cell line compared with the two resistant cell lines. In conclusion, a novel yet reliable method for the measurement of intracellular 18F-FDG via GS has been developed, and our results indicate that 18F-FDG uptake is associated with radiation and cetuximab response in HNSCC.
format Online
Article
Text
id pubmed-6788167
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-67881672019-10-16 In vitro measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18F-FDG, gamma spectrometry and PET/CT Matic, Natasa Ressner, Marcus Wiechec, Emilia Roberg, Karin Oncol Lett Articles The standard treatment for head and neck squamous cell carcinoma (HNSCC) is radiotherapy, often in combination with chemotherapy or surgery. However, a novel monoclonal antibody, cetuximab (Erbitux(®)), has also been approved for patient therapy. The aim of present study was to develop an in vitro method for the measurement of 18F-fluoro-2deoxy-D-glucose (FDG) to determine if cellular 18F-FDG uptake is associated with response to radiotherapy or cetuximab treatment. In the current study, HNSCC cell lines were treated with radiation or with cetuximab. Next, the uptake of 18F-FDG was measured using a gamma spectrometer (GS). Thereafter, uptake after radiation was measured first with GS and then compared with positron emission tomography (PET)/computed tomography (CT) imaging. Furthermore, the mRNA expression of glucose transporter 1 (GLUT1) was measured following cetuximab treatment via reverse transcription-quantitative PCR. A study protocol was developed to measure the cellular uptake of 18F-FDG via gamma-ray spectrometry and comparable results were obtained with those of clinical PET/CT. The results revealed a decrease in 18F-FDG after radiation and cetuximab treatment. The uptake of 18F-FDG following cetuximab treatment was significantly lower in the cetuximab-sensitive cell line UT-SCC-14 compared with the cetuximab-resistant cell lines UT-SCC-2 and UT-SCC-45. Furthermore, after treatment with cetuximab for 24 and 48 h, a significant increase in GLUT1 expression was detected in the sensitive cell line compared with the two resistant cell lines. In conclusion, a novel yet reliable method for the measurement of intracellular 18F-FDG via GS has been developed, and our results indicate that 18F-FDG uptake is associated with radiation and cetuximab response in HNSCC. D.A. Spandidos 2019-11 2019-09-24 /pmc/articles/PMC6788167/ /pubmed/31620196 http://dx.doi.org/10.3892/ol.2019.10916 Text en Copyright: © Matic et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Matic, Natasa
Ressner, Marcus
Wiechec, Emilia
Roberg, Karin
In vitro measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18F-FDG, gamma spectrometry and PET/CT
title In vitro measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18F-FDG, gamma spectrometry and PET/CT
title_full In vitro measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18F-FDG, gamma spectrometry and PET/CT
title_fullStr In vitro measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18F-FDG, gamma spectrometry and PET/CT
title_full_unstemmed In vitro measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18F-FDG, gamma spectrometry and PET/CT
title_short In vitro measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18F-FDG, gamma spectrometry and PET/CT
title_sort in vitro measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18f-fdg, gamma spectrometry and pet/ct
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788167/
https://www.ncbi.nlm.nih.gov/pubmed/31620196
http://dx.doi.org/10.3892/ol.2019.10916
work_keys_str_mv AT maticnatasa invitromeasurementofglucoseuptakeafterradiationandcetuximabtreatmentinheadandneckcancercelllinesusing18ffdggammaspectrometryandpetct
AT ressnermarcus invitromeasurementofglucoseuptakeafterradiationandcetuximabtreatmentinheadandneckcancercelllinesusing18ffdggammaspectrometryandpetct
AT wiechecemilia invitromeasurementofglucoseuptakeafterradiationandcetuximabtreatmentinheadandneckcancercelllinesusing18ffdggammaspectrometryandpetct
AT robergkarin invitromeasurementofglucoseuptakeafterradiationandcetuximabtreatmentinheadandneckcancercelllinesusing18ffdggammaspectrometryandpetct